GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Net Interest Income (for Banks)

NurExone Biologic (TSXV:NRX) Net Interest Income (for Banks)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


NurExone Biologic Business Description

Industry
Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer